acenocoumarol / Generic mfg. - LARVOL DELTA

Anticoagulation therapeutic ranges and clinical outcomes in patients with a mechanical heart valve treated with vitamin K antagonists. (PubMed, Thromb Haemost) - "A lower therapeutic range does not apparently increase thromboembolic risk in most MHV patients but may be associated with a higher thromboembolic risk in higher risk patients. Lower therapeutic ranges were not associated with lower bleeding risk."

Clinical data • Journal • Cardiovascular

Comparative Outcomes of Apixaban and Acenocoumarol in Advanced Chronic Kidney Disease and Atrial Fibrillation: A Retrospective Observational Study. (PubMed, J Clin Med) - "These findings support apixaban as a safer and more practical anticoagulant option in advanced CKD, consistent with its limited renal clearance and reduced influence on the inflammation-coagulation axis. Further multicenter prospective studies are warranted to validate these real-world results."

Journal • Observational data • Retrospective data • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Inflammation • Nephrology • Renal Disease • Thrombosis

Leukocytoclastic Vasculitis Associated with Coumarin Derivatives: A Case Report. (PubMed, Hosp Pharm) - "Coumarin derivatives, including warfarin and acenocoumarol, are widely used oral anticoagulants that inhibit vitamin K-dependent coagulation factors. Ultimately, transitioning to apixaban led to the complete resolution of symptoms. This case underscores the importance of early recognition of drug-induced vasculitis and highlights the need for individualised anticoagulation strategies in patients with hypersensitivity reactions."

Journal • Cardiovascular • Heart Failure • Hematological Disorders • Immunology • Infectious Disease • Vasculitis

Exploring acenocoumarol and silodosin in non-small cell lung cancer: Insights into EGFR-linked signaling mechanisms. (PubMed, F1000Res) - "In the xenograft study, tumor size, body weight, and organ weight were significantly attenuated by the test drugs compared with the standard cisplatin. KRAS and ERK2 are components of EGFR-associated signaling pathways. Hence, acenocoumarol and silodosin can be further explored as repurposed candidates in future preclinical and clinical studies."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CASP3 • KRAS

Time in therapeutic range as predictor of early left-ventricular thrombosis resolution: a retrospective cohort study. (PubMed, Intern Emerg Med) - "The cumulative incidence of early LVT resolution was higher in patients with TTR values ≥ 56% (57.1%; 95% confidence interval-CI 32.8-75.5%) than < 56% (30.3%; 95% CI 15.6-46.4%).The quality of VKAs anticoagulation may be a relevant driver for early LVT resolution. TTR evaluation appears to have a slightly greater accuracy compared to INR variability."

Journal • Retrospective data • Cardiovascular • Hematological Disorders • Thrombosis

Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS (clinicaltrials.gov) - P=N/A | N=150 | Recruiting | Sponsor: McMaster University | Trial completion date: Dec 2027 ➔ Dec 2029 | Trial primary completion date: Jul 2027 ➔ Jul 2029

Trial completion date • Trial primary completion date • Cardiovascular • Genetic Disorders • Hematological Disorders • Thrombosis

Point-of-Care Agitated Saline Contrast Echocardiography in the Diagnosis of Respiratory Failure: A Case of Hepatopulmonary Syndrome With Decompensated Heart Failure. (PubMed, Cureus) - "Past medical history was notable for dilated alcoholic cardiomyopathy, heart failure with reduced ejection fraction (New York Heart Association (NYHA) class II, left ventricle ejection fraction (LVEF) 30%), permanent atrial fibrillation (AF) (on bisoprolol and anticoagulation with acenocoumarol), and a prior mitral valve prosthesis...However, despite high-flow nasal oxygen therapy, subsequent noninvasive ventilation(NIV) (fraction of inspired oxygen (FiO₂) 1.0), and pharmacologic therapy with furosemide resulting in satisfactory diuresis (250 mL/h) and reduced pulmonary congestion on lung ultrasound, oxygenation improved only minimally (PaO₂ up to 40 mmHg), and dyspnea persisted.  Given the presence of cirrhosis with portal hypertension and refractory hypoxemia, and that a workup for HPS had not yet been performed, a bedside agitated-saline contrast echocardiography was performed at the point of care. Microbubbles appeared in the left atrium (LA) and..."

Journal • Addiction (Opioid and Alcohol) • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Fibrosis • Gastroenterology • Heart Failure • Hepatology • Hypertension • Immunology • Liver Cirrhosis • Portal Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Transplantation

Fetal posterior cerebral artery infarction due to carotid dissection: a case report. (PubMed, J Med Case Rep) - "Fetal posterior cerebral artery and internal carotid artery dissection are frequent separately, but their co-occurrence is exceptional. This report broadens the spectrum of internal carotid artery dissection and discusses the role of fetal posterior cerebral artery in ischemic stroke pathogenesis."

Journal • Cardiovascular • CNS Disorders • Hypertension • Ischemic stroke • Mood Disorders

Time for a Paradigm Shift in Vitamin K Antagonist Reversal - Embracing TGA over INR for Optimal Outcomes? (ASH 2023) - "Participants were pre-treated for 10 days with acenocoumarol to achieve an INR between 2 and 3 (± 10% inclusive)... After 4F-PCC infusion, clotting factors II, VII, IX and X showed dose-dependent increases at 30 min post-dose. Correspondingly, a dose-dependent TGA response was observed; 4F-PCC resulted in restoration to levels measured before anticoagulation with VKA. The degree of INR normalization appeared to be slightly more pronounced in the higher dosed 4F-PCC group."

Thrombosis

Apixaban Vs Vitamin K Antagonist As Anticoagulant Therapy in Patients with End-Stage Kidney Disease on Hemodialysis and with Atrial Fibrillation (ASH 2023) - "Patients in the VKA group received Acenocoumarol. There were no significant differences regarding in all-cause mortality, 18.8% versus 21.5% respectively. CONCLUSIONS Compared to VKA, our findings suggest that low dose of apixaban is a safe and effective alternative in patients with AF and ESKD on hemodialysisis and low dose of apixaban showed predictable pharmacokinetic."

Clinical • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Ischemic stroke • Myocardial Infarction • Nephrology • Renal Disease

Safety of contraception among women using anticoagulant therapy: an updated systematic review. (PubMed, Contraception) - "Women on anticoagulant therapy are at risk for recurrent thrombosis and bleeding, which might be further exacerbated with use of certain contraceptive methods. Additional evidence is needed on safety of concurrent use of anticoagulant medications and contraceptives."

Journal • Review • Cardiovascular • Hematological Disorders • Long-acting Reversible Contraceptives • Venous Thromboembolism

RISK OF ISCHAEMIC STROKE AND INTRACRANIAL BLEEDING WITH DIRECT-ACTING ORAL ANTICOAGULANTS AND WARFARIN COMPARED TO ACENOCOUMAROL (WSC 2025) - "Background and Aims: Most clinical trials and observational studies conducted with direct-acting oral anticoagulants (DOAC: dabigatran, rivaroxaban, apixaban and edoxaban) have used warfarin as the comparator drug. The results suggest that conclusions drawn from studies using warfarin as the reference drug should not be automatically extrapolated to acenocoumarol."

Atrial Fibrillation • Cardiovascular • Ischemic stroke

Monitoring and Follow-Up of Patients on Vitamin K Antagonist Oral Anticoagulant Therapy Using Artificial Intelligence: The AIto-Control Project. (PubMed, J Clin Med) - "Background: Vitamin K antagonist oral anticoagulant (VKA) therapy, using warfarin or acenocoumarol in our health system, is indicated, according to clinical guidelines, for the prophylaxis of thromboembolic events. Additionally, it aims to ease the workload on both primary care and hospital services. These outcomes will be achieved through the involvement of advanced practice nurses who will supervise app-based monitoring and patient education."

Journal • Cardiovascular

Personalized management of acenocoumarol dosage using eGFR: Analysis of INR data in a cohort of 204 patients. (PubMed, Int J Clin Pharmacol Ther) - "Renal function, as measured by BSA-adjusted eGFR, is a critical determinant of acenocoumarol dose requirements. These findings support the inclusion of renal function in future acenocoumarol dose calculators and emphasize the importance of individualized dosing strategies."

Journal • Chronic Kidney Disease • Nephrology • Renal Disease

Insights into the alteration of vaginal microbiota and metabolites in pregnant woman with preterm delivery: prospective cohort study. (PubMed, Front Cell Infect Microbiol) - "In addition, vaginal metabolomics-based LC-Orbitrap-MS/MS revealed that the contents of 2-Piperidone, Melphalan, N-acetylputrescine, Obatoclax, Eurostoside, Pregnanediol 3-O-glucuronide, O-Phospho-L-serine, 1-Kestose and N-arachidonylglycine were significantly decreased in the PrPG group compared with the PrTG group, while Acenocoumarol, Isopyrazam, Pentosidine, hexose, 7-Hydroxymitragynine, PE, Tamoxifen and 1-Deoxynojirimycin contents were significantly increased. These results suggest that specific bacterial species and metabolites may serve as potential biomarkers for preterm birth prediction, and approve the theoretical basis for the intervention of preterm birth."

Journal

Tyrosine Kinase Inhibitor Treatment of a Patient with Chronic Myeloid Leukemia and Congenital Thrombophilia. (PubMed, Hematol Rep) - "Case Presentation: A 33-year-old woman with congenital thrombophilia (type I protein S deficiency and heterozygous Factor V Leiden mutation) and a history of VTE on long-term anticoagulation with acenocoumarol presented with CML. She exhibited primary resistance to first-line imatinib and poor tolerance with suboptimal response to second-line bosutinib... This case highlights the importance of individualized, multidisciplinary management in CML patients with coexisting thrombophilia. Asciminib, with its favorable cardiovascular safety profile, represents a promising therapeutic option in high-risk patients where other TKIs may be contraindicated due to resistance, intolerance, or thrombotic risk."

Journal • Cardiovascular • Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Venous Thromboembolism • PROS1

Hemorrhage Risk Associated with Anticoagulant and Antiplatelet Drug Combinations: Insights from the USFDA Adverse Event Reporting System. (PubMed, J Clin Med) - "Anticoagulants analyzed included warfarin, rivaroxaban, dabigatran, apixaban, edoxaban, betrixaban, and acenocoumarol; antiplatelets included aspirin, clopidogrel, ticagrelor, cilostazol, prasugrel, and dipyridamole. While our findings highlight potential safety signals related to hemorrhage with antithrombotic drug combinations, they remain hypothesis-generating and should not be interpreted as causal associations. Instead, they provide an initial basis for further validation in well-designed clinical cohorts where comorbidities can be adequately accounted for."

Adverse events • Journal • Hematological Disorders

Thrombocheck: a drug-drug interactions guide for cardiologists prescribing antithrombotic therapy (ESC-WCC 2025) - " First, a clinical pharmacist and a physician independently analysed the literature on DDI for 8 AT: 5 OAC (rivaroxaban, apixaban, edoxaban, dabigatran and acenocoumarol) and 3 AA (clopidogrel, ticagrelor and prasugrel). Aspirin was excluded as it is not known for PK DDI... Antithrombotic therapies are susceptible to numerous DDI. This simple yet important tool can help cardiologists minimize significant DDI when prescribing new AT, guiding them toward safer et more effective treatment options."

Cardiovascular

The key determinants of oral anticoagulant treatment experience in atrial fibrillation patients (ESC-WCC 2025) - "NOACs were used by 53% of patients, mainly rivaroxaban (38%), apixaban (11%), and edoxaban (4%), while 47% used VKAs, primarily warfarin (25%) and acenocoumarol (22%). The study highlights that socioeconomic factors, particularly education level and household income, play a crucial role in the perceived convenience and satisfaction with OAC therapy in AF patients. Patients receiving VKA therapy reported lower treatment convenience, possibly due to the need for frequent monitoring and dietary restrictions.These findings underscore the importance of individualized patient support and education to optimize adherence and overall treatment experience in anticoagulated AF patients."

Clinical • Atrial Fibrillation • Cardiovascular • Dyslipidemia

ARGONAUT: Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus (clinicaltrials.gov) - P3 | N=340 | Active, not recruiting | Sponsor: Centre Hospitalier Universitaire de Nīmes | Recruiting ➔ Active, not recruiting | Trial completion date: Apr 2025 ➔ Feb 2026

Enrollment closed • Trial completion date • Cardiovascular • Heart Failure • Thrombosis

Comparative clinical outcomes of acenocoumarol versus direct oral anticoagulants (DOACs) and warfarin in patients with atrial fibrillation: real-world-evidence (SIESTA-A study). (PubMed, Front Pharmacol) - "The aim of this study was to evaluate the effectiveness and safety of direct oral anticoagulants (DOACs: dabigatran, rivaroxaban, apixaban and edoxaban) and warfarin versus acenocoumarol in patients with atrial fibrillation under real-world clinical practice conditions. Although DOACs were clearly associated with a lower risk of intracranial bleeding compared to acenocoumarol, our data did not reveal a significant reduction in thromboembolic events. Warfarin was found to be both less effective and less safe than acenocoumarol."

Clinical data • HEOR • Journal • Real-world evidence • Atrial Fibrillation • Cardiovascular • Gastroenterology • Ischemic stroke • Pulmonary Embolism • Respiratory Diseases

Acute Coronary Syndrome in a Young Woman With Protein S Deficiency and Von Willebrand Disease Type 1: A Case of Mixed Hemostatic Disorders. (PubMed, Cureus) - "She underwent percutaneous intervention with multiple stents and commenced anticoagulation therapy with acenocoumarol following the identification of partial protein S deficiency (56%)...The anticoagulant regimen was switched to dabigatran...The patient achieved a favorable clinical outcome, characterized by symptom resolution, an absence of new thrombotic or bleeding events, and partial biochemical recovery. This case highlights the importance of comprehensive hematological investigations in young patients presenting with atypical arterial thrombotic events."

Journal • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Hematological Disorders • Hemophilia • Myocardial Infarction • Thrombosis • PROS1

Optimization of vitamin K antagonist treatment: Near patient monitoring versus standard of care a parallel group clinical trial in older patients with atrial fibrillation. (PubMed, Eur J Clin Pharmacol) - "NPTM of VKA treatment in AF-patients does not result in an improved TTR when compared to SOC. All-cause death, total number of minor bleedings and all non-major bleedings may be reduced in NPTM, although the study was not powered for these secondary outcomes. Future studies are needed to determine the cost-effectiveness of NTPM versus SOC."

Journal • Atrial Fibrillation • Cardiovascular • Geriatric Disorders

A comparison of antiplatelet and oral anticoagulation strategies to prevent cerebral microembolism after transcatheter aortic valve implantation: the AUREA trial. (PubMed, EuroIntervention) - "In patients without an indication for OAC, an OAC strategy for 3 months post-TAVI did not show any benefit over an antiplatelet strategy in preventing cerebral microembolism. Patients treated with DAPT showed a lower mean volume of brain damage on DW-MRI during the 90 days following TAVI compared to those treated with acenocoumarol."

Clinical • Journal • Cardiovascular • CNS Disorders • Vascular Neurology

Cost-effectiveness of dabigatran for thromboembolic events prevention in atrial fibrillation patients in Chile. (PubMed, Cost Eff Resour Alloc) - "Dabigatran is cost-effective and dominates both rivaroxaban and apixaban at current publicly available prices in Chile. In addition, we expect dabigatran-idarucizumab is also expected to be cost-effective for Chilean health system when is compared against acenocoumarol-PCC as reversal agents."

HEOR • Journal • Atrial Fibrillation • Cardiovascular • Hematological Disorders